Related references
Note: Only part of the references are listed.mlr3proba: an R package for machine learning in survival analysis
Raphael Sonabend et al.
BIOINFORMATICS (2021)
Mutational profiles of metastatic colorectal cancer treated with FOLFIRI plus cetuximab or bevacizumab before and after secondary resection (AIO KRK 0306; FIRE-3)
Arndt Stahler et al.
INTERNATIONAL JOURNAL OF CANCER (2021)
Development and validation of a robust epithelial-mesenchymal transition (EMT)-related prognostic signature for hepatocellular carcinoma
Shimin Chen et al.
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY (2021)
Factors That Influence Conversion to Resectability and Survival After Resection of Metastases in RAS WT Metastatic Colorectal Cancer (mCRC): Analysis of FIRE-3-AIOKRK0306
Dominik Paul Modest et al.
ANNALS OF SURGICAL ONCOLOGY (2020)
Investigating the concordance in molecular subtypes of primary colorectal tumors and their matched synchronous liver metastasis
Andreas Schlicker et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Single-nucleotide variants, tumour mutational burden and microsatellite instability in patients with metastatic colorectal cancer: Next-generation sequencing results of the FIRE-3 trial
Arndt Stahler et al.
EUROPEAN JOURNAL OF CANCER (2020)
Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial
S. Stintzing et al.
ANNALS OF ONCOLOGY (2019)
Epithelial Mesenchymal Transition in Tumor Metastasis
Vivek Mittal
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 13 (2018)
Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS
T. Yoshino et al.
ANNALS OF ONCOLOGY (2018)
Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study
S. Stintzing et al.
EUROPEAN JOURNAL OF CANCER (2017)
Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer
Rodrigo Dienstmann et al.
NATURE REVIEWS CANCER (2017)
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
E. Van Cutsem et al.
ANNALS OF ONCOLOGY (2016)
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial
Sebastian Stintzing et al.
LANCET ONCOLOGY (2016)
Adjuvant chemotherapy for resected colorectal cancer metastases: literature review and meta-analysis
Giovanni Brandi et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
Epithelial-mesenchymal transition in colorectal cancer metastasis: A system review
Hui Cao et al.
PATHOLOGY RESEARCH AND PRACTICE (2015)
Metachronous metastases from colorectal cancer: a population-based study in North-East Netherlands
Marloes A. G. Elferink et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2015)
Epithelial-to-mesenchymal transition and the cancer stem cell phenotype: insights from cancer biology with therapeutic implications for colorectal cancer
V. J. Findlay et al.
CANCER GENE THERAPY (2014)
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
Volker Heinemann et al.
LANCET ONCOLOGY (2014)
Incidence and patterns of recurrence after resection for cure of colonic cancer in a well defined population
S. Manfredi et al.
BRITISH JOURNAL OF SURGERY (2006)
Epidemiology and management of liver metastases from colorectal cancer
Sylvain Manfredi et al.
ANNALS OF SURGERY (2006)
Share Paper
